HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Public ClinicalTrials.gov record NCT06001385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
Study identification
- NCT ID
- NCT06001385
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 313 participants
Conditions and interventions
Conditions
Interventions
- Busulfan Drug
- Fludarabine Drug
- PBSC Hematopoietic Stem Cell Transplantation (HSCT) Procedure
- Post-Transplant Cyclophosphamide Drug
- Mesna Drug
- Tacrolimus Drug
- Mycophenolate Mofetil Drug
- Patient Reported Outcomes Other
- Melphalan Drug
- Total-body irradiation Radiation
- Cyclophosphamide Drug
Drug · Procedure · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2023 (Actual)
- Primary completion
- Dec 24, 2026 (Estimated)
- Completion
- Dec 30, 2026 (Estimated)
- Last update posted
- Aug 17, 2026
2023 – 2026
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| Honor Health | Scottsdale | Arizona | 85258 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| Stanford University | Stanford | California | 94305 | — |
| Colorado Blood Cancer Institute at Presbyterian St. Luke's | Denver | Colorado | 80218 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| University of Miami Sylvester Cancer Center | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Greenbaum Cancer Center University of Maryland | Baltimore | Maryland | 21201 | — |
| Tufts University | Boston | Massachusetts | 02155 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| Barnes Jewish Hospital / Washington University | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center - Adults | New York | New York | 10065 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Ohio State Medical Center | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| The Center for Bone Marrow Transplantation at Geisinger | Danville | Pennsylvania | 17822 | — |
| Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| TriStar Centennial | Nashville | Tennessee | 37203 | — |
| St. David's South Austin Medical Center | Austin | Texas | 78704 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Methodist Hospital San Antonio | San Antonio | Texas | 78229 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| Froedtert & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06001385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06001385 live on ClinicalTrials.gov.